BioSpace News Archive

WUHAN GENERAL GROUP, INC. is pleased to announce, that effective June 30 th , 2020, it has signed a letter of intent to pursue a Partnership where Jugular

Celcuity Inc. announced today that it will host a call to discuss its CELsignia pathway activity test for ovarian cancer on Monday, July 13, 2020 at 1:00 pm Eastern Time.

Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the second quarter ended June 30, 2020.

FT. MYERS, FL / ACCESSWIRE / July 1, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020. The Company has scheduled a web-cast and conference call to discuss their first quarter results on Tuesday, July 28, 2020 at 8:30 AM EDT.

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that on June 30, 2020 it closed its previously announced underwritten offering of 6,520,000 shares of its common stock and warrants to purchase up to an aggregate of 3,260,000 shares of the its common stock. Each share of common stock was sold together with a warrant to purchase 0.5

Halberd Corporation (OTC PINK:HALB) announced the establishment of a subsidiary in the United Kingdom to facilitate access to European research facilities and markets. The subsidiary is Halberd Corporation UK, Ltd.

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced today that it will host a call to discuss its CELsignia pathway activity test for ovarian cancer on Monday, July 13, 2020 at 1:00 pm Eastern Time.

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 14,500 shares of Calithera’s common stock, at a per share exercise price of $5.28, the closing trading price on June 30, 2020.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 70,000 shares of BioCryst common stock on June 30, 2020 as inducements material to each employee entering into employment with BioCryst.

DalCor Pharmaceuticals today announced the appointment of Dr. David G. Kallend as Chief Scientific Officer effective July 1, 2020. Dr. Kallend joins DalCor from The Medicines Company where he held the position of Senior Vice President and Chief Medical Officer.